Cytokinetics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. The company’s lead drug candidate is in phase II clinical development for the potential treatment of heart failure. Other drug candidates include CK-2017357 for treating diseases or medical conditions associated with skeletal muscle weakness or wasting, which is in Phase II clinical trials; and CK-2127107, a skeletal sarcomere activator, which is in non-clinical stage. The company is also developing mitotic kinesin inhibitors, including ispinesib, SB-743921, and GSK-923295 for the treatment of cancer. For more information visit the company’s Web site at www.cytokinetics.com.

Rodman & Renshaw is a full-service investment bank dedicated to providing corporate finance, strategic advisory, and related services to public and private companies across multiple sectors and regions. Rodman also provides research, sales, and trading services. According to Sagient Research Systems, Rodman has been ranked the #1 Placement Agent in terms of the aggregate number of PIPE and RD financing transactions completed every year since 2005. For more information on Rodman & Renshaw, visit www.rodmanandrenshaw.com.

Let us hear your thoughts below: